ClinicalTrials.gg
CompletedNCT04429555Updated Oct 30, 2024Results posted

Efficacy, Safety, Tolerability, and Biomarkers of Ibudilast (MN-166) in Patients Hospitalized With COVID-19 at Risk for ARDS

A Phase 2 interventional study of Ibudilast and Placebo in Pneumonia, Viral, sponsored by MediciNova. Completed at 2 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-10-30.

Primary conditionCOVID-19Registry: Pneumonia, ViralReclassifiedWhy we changed it
Registry
Pneumonia, Viral — the first condition term the registry derived for this study.
ClinicalTrials.gg
COVID-19
Why
  1. The study's title name COVID-19, a narrower term within Pneumonia, Viral.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by MediciNova · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
34
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 1,860 studies in COVID-19 with a site in United States — 120 open to participants now, 210 under way, 16 of them phase 3. COVID-19 · United States.

Enrollment
925th of 1,322
34 · median 92
Started
2021
with 503 others
Phase 2
350 of 1,860
15 open now
Registered
434th of 1,860
by date

Among the 1,860 studies in COVID-19 with a site in United States, this one is the 925th largest by enrollment of the 1,322 interventional ones that give a count, is one of 504 that started in 2021, is one of 350 in phase 2, and was the 434th registered.

COVID-19

7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.

Browse COVID-19 studies →

Open to participants now

120 of the 1,860 studies in COVID-19 with a site in United States are open now. Recruiting first, the newest first:

115 more — sign in →

All 120 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,860 studies in COVID-19 with a site in United States, or all of them as a file.
02

Study summary

The goal of this study is to evaluate the effects of Ibudilast (MN-166) versus placebo in hospitalized patients infected with COVID-19 at risk for developing acute respiratory distress syndrome (ARDS) receiving standard of care (including anticoagulation therapy) by measuring the following outcomes: 1) the need for oxygen therapy at Days 7, 14, and 28, 2) clinical status as measured by the National Institute of Allergy and Infectious Diseases (NIAID) ordinal scale at Days 7, 14, and 28, and 3) safety (as measured by incidence of adverse events and clinical laboratory findings) and tolerability of Ibudilast.

Read the detailed description

This is a randomized (1:1) double-blind, placebo-controlled, parallel-group study evaluating the efficacy of Ibudilast to prevent ARDS in hospitalized patients infected with COVID-19 who are at risk for developing ARDS. The study will consist of a Screening Phase, Double-Blind Treatment Phase, and Follow-up Phase. Following the Screening Phase, if the participant meets eligibility criteria, they will be randomly assigned to Ibudilast or matching placebo. Participants will receive Ibudilast 100 mg/d (50 mg twice a day) or placebo every day for 7 days. Upon completion of the 7-day Treatment Phase, subject will be followed-up at Day 14 and at Day 28. Participants discharged prior to Day 7 will be given the remainder of their study medication (Ibudilast or placebo) to be taken at home twice daily until Day 7 and will be given a pulse oximeter to measure their oxygen levels once daily until Day 14.

The following screening assessments will be performed upon signing the Informed Consent Form (ICF): inclusion/exclusion criteria review, physical exam, vital signs and oxygen use, clinical status using the NIAID ordinal scale, 12-lead ECG, blood collection for plasma biomarkers. A complete blood count (CBC), comprehensive metabolic panel (CMP), D-dimer and coagulation tests will also be drawn. A serum pregnancy test will be given to pre-menopausal female participants. Concomitant medications taken within the last 7 days prior to study drug administration will be recorded.

During the Treatment Phase, hospitalized participants will be treated with Ibudilast or placebo for a 7-day period plus standard of care and anticoagulation therapy. During the Treatment Phase, participants will undergo study-related procedures including physical exam, ECG, oxygen use assessment, biomarkers and pharmacokinetic sample draws, CBC, CMP, D-dimer blood collection, clinical status using the NIAID scale, and information on adverse events and concomitant medications will be recorded.

On Study Day 14, conduct physical examination, clinical status, vital signs and oxygen use, ECG, CBC, CMP, D-dimer, and coagulation tests, biomarkers, AE and concomitant medications review. On Day 28, participant's clinical status and survival status will be recorded.

If the participant is discharged before Day 7, they will be given the remainder of their study drug to take at home for up to 7 days, and the Sponsor will supply a pulse oximeter to participants to measure their oxygen levels once daily until Day 14.

03

Conditions studied

  • Pneumonia, Viral

Browse trials for

Keywords

  • COVID-19
  • Acute respiratory distress syndrome
  • Pneumonia
04

In context

COVID-19 Reclassified

7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.

This study's enrollment of 34 is below the median of 102 across 4,369 interventional studies indexed under COVID-19.

Browse COVID-19 studies →

Lead sponsor

MediciNova is the lead sponsor of 17 studies on the registry; none are open to participants now.

Compared within COVID-19, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Pneumonia, Viral. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • SARS-CoV-2 infection confirmed with WHO criteria (including a positive PCR of any specimen, e.g., blood, respiratory, stool, urine, or any other body fluid)
  • Chest imaging (radiograph, computerized tomography (CT) scan or lung ultrasound) with abnormalities consistent with COVID-19 pneumonia
  • Oxygen saturation (SpO2) ≤92% on room air (RA), respiratory rate ≥24 breaths per min on RA, and/or requirement for supplemental oxygen
  • At least 1 risk factor which may put patient at higher risk for more severe illness from COVID-19: Age > 65, underlying serious heart disease, chronic lung disease, moderate to severe asthma, of ≥40, or diabetes

Exclusion criteria

Exclusion Criteria:

  • Suspected active bacterial, fungal, viral, or other cause of respiratory failure other than COVID-19
  • Subject is already intubated and on ventilator support
  • Known or suspected with immunosuppressant medications or chemotherapeutic agents
  • Patient is receiving dialysis treatment
  • On a home ventilator support or continuous domiciliary oxygen therapy for baseline lung disease
  • Active tuberculosis infection
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
34 participants (actual)

Study arms

  • Experimental
    Active Treatment Group

    Drug: Ibudilast

  • Placebo comparator
    Placebo Treatment Group

    Drug: Placebo

Interventions

  • 50 mg (5 x 10 mg capsules) twice daily for 7 days

    Also known as: MN-166

  • DrugPlacebo

    0 mg (5 matching capsules) twice daily for 7 days

07

What researchers measure

Primary outcomes

  1. Number of Participants Free From Respiratory Failure at Day 7

    Participants were considered "responders" if they did not meet the need for supplemental oxygen requirements (invasive mechanical ventilation, non-invasive ventilation, high-flow oxygen, or ECMO, CPAP, BiPAP, nasal cannula) at the end of the 7-day double-blind treatment.

    Time frame: Day 7

  2. Number of Participants With at Least a 1-point Improvement in Clinical Status on Day 7

    Number (percentage) of participants with at least a 1-point improvement in clinical status on Day 7. Clinical status is measured by the National Institute of Allergy and Infectious Disease (NIAID) 8-Point Ordinal Scale: 1=Not hospitalized, no limitations on activities; 2=Not hospitalized, limitation on activities and/or requiring home oxygen; 3=Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 4=Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise) 5=Hospitalized, Hospitalized, requiring supplemental oxygen; 6=Hospitalized, on non-invasive ventilation or high flow oxygen devices; 7=Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 8=Death.

    Time frame: Day 7

Secondary outcomes

  1. Number of Participants Receiving Mechanical Ventilation or Intubation

    Number (percentage) of participants receiving mechanical ventilation or intubation after starting study drug.

    Time frame: Days 7, 14, and 28

  2. All-cause Mortality

    Number of reported participant deaths

    Time frame: Day 1 to Day 60

  3. Number of Participants Discharged From Hospital at Days 7, 14, and 28

    Number (percentage) of participants discharged from hospital at Days 7, 14, and 28

    Time frame: Days 7, 14, and 28

08

Results

Posted Oct 30, 2024

Participant flow

Participant flow — Overall Study
MilestoneIbudilast (MN-166)Placebo
Started1717
Completed1515
Not completed22
Withdrew: Death02
Withdrew: Other20

Outcome measures

PrimaryNumber of Participants Free From Respiratory Failure at Day 7

Participants were considered "responders" if they did not meet the need for supplemental oxygen requirements (invasive mechanical ventilation, non-invasive ventilation, high-flow oxygen, or ECMO, CPAP, BiPAP, nasal cannula) at the end of the 7-day double-blind treatment.

Time frame:
Day 7
Reported as:
Count of participants · Participants
Number of Participants Free From Respiratory Failure at Day 7
ParticipantsIbudilast (MN-166)Placebo
Number of Participants Free From Respiratory Failure at Day 7126
PrimaryNumber of Participants With at Least a 1-point Improvement in Clinical Status on Day 7

Number (percentage) of participants with at least a 1-point improvement in clinical status on Day 7. Clinical status is measured by the National Institute of Allergy and Infectious Disease (NIAID) 8-Point Ordinal Scale: 1=Not hospitalized, no limitations on activities; 2=Not hospitalized, limitation on activities and/or requiring home oxygen; 3=Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 4=Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise) 5=Hospitalized, Hospitalized, requiring supplemental oxygen; 6=Hospitalized, on non-invasive ventilation or high flow oxygen devices; 7=Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 8=Death.

Time frame:
Day 7
Reported as:
Count of participants · Participants
Number of Participants With at Least a 1-point Improvement in Clinical Status on Day 7
ParticipantsIbudilast (MN-166)Placebo
Number of Participants With at Least a 1-point Improvement in Clinical Status on Day 7128
SecondaryNumber of Participants Receiving Mechanical Ventilation or Intubation

Number (percentage) of participants receiving mechanical ventilation or intubation after starting study drug.

Time frame:
Days 7, 14, and 28
Reported as:
Count of participants · Participants
Number of Participants Receiving Mechanical Ventilation or Intubation
ParticipantsIbudilast (MN-166)Placebo
Day 713
Day 1412
Day 2811
SecondaryAll-cause Mortality

Number of reported participant deaths

Time frame:
Day 1 to Day 60
Reported as:
Count of participants · Participants
All-cause Mortality
ParticipantsIbudilast (MN-166)Placebo
All-cause Mortality02
SecondaryNumber of Participants Discharged From Hospital at Days 7, 14, and 28

Number (percentage) of participants discharged from hospital at Days 7, 14, and 28

Time frame:
Days 7, 14, and 28
Reported as:
Count of participants · Participants
Number of Participants Discharged From Hospital at Days 7, 14, and 28
ParticipantsIbudilast (MN-166)Placebo
Day 7115
Day 141311
Day 281314

Adverse events

Collected over Adverse events occurring from the time of the first dose through 7 days after the last dose of MN-166 were recorded.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
MN-166 (Ibudilast)0/17 (0%)5/17 (29.4%)13/17 (76.5%)
Placebo2/17 (11.8%)14/17 (82.4%)14/27 (51.9%)
Most frequent serious events
Most frequent serious events
EventMN-166 (Ibudilast)Placebo
Acute Kidney InjuryRenal and urinary disorders0/173/17
Respiratory failureRespiratory, thoracic and mediastinal disorders2/173/17
ConstipationGastrointestinal disorders0/172/17
PneumoniaRenal and urinary disorders2/172/17
Ischaemic hepatitisHepatobiliary disorders0/171/17
BacteraemiaInfections and infestations0/171/17
DiverticulitisGastrointestinal disorders1/170/17
PneumomediastinumRespiratory, thoracic and mediastinal disorders0/171/17
ShockVascular disorders0/171/17
Most frequent other events
Showing 10 of 42
Most frequent other events
EventMN-166 (Ibudilast)Placebo
BradycardiaCardiac disorders7/173/17
Transaminases increasedInvestigations1/174/17
LeukocytosisBlood and lymphatic system disorders0/173/17
HyperglycaemiaEndocrine disorders0/173/17
DiarrhoeaGastrointestinal disorders3/172/17
Sinus bradycardiaCardiac disorders2/171/17
HeadacheNervous system disorders1/172/17
HypoxiaRespiratory, thoracic and mediastinal disorders0/172/17
HypotensionVascular disorders0/172/17
EosinophiliaBlood and lymphatic system disorders1/170/17

Baseline characteristics

Age, Continuous
Age, Continuous(years)Ibudilast (MN-166)PlaceboTotal
Mean58.71 ± 11.3261.06 ± 12.1659.88 ± 11.63
Sex: Female, Male
Sex: Female, Male(Participants)Ibudilast (MN-166)PlaceboTotal
Female9817
Male8917
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Ibudilast (MN-166)PlaceboTotal
Hispanic or Latino7310
Not Hispanic or Latino101424
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Ibudilast (MN-166)PlaceboTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander101
Black or African American123
White101323
More than one race000
Unknown or Not Reported527
Region of Enrollment
Region of Enrollment(Participants)Ibudilast (MN-166)PlaceboTotal
United States171734
09

Study locations

2 sites
  • Denver Health and Hospital Authority
    Denver, Colorado 80204, United States
  • Yale University School of Medicine
    New Haven, Connecticut 06520, United States
10

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2021 to primary completion in Jun 2022, 17 months.

Results were first posted in Oct 2024, 2 years 4 months after primary completion.

Of 224 industry-sponsored phase 2 interventional studies under COVID-19, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 14. This study's 17 months is above that.

Counting every sponsor, half of 583 studies reached it within 9 months; a quarter within 5 and three quarters within 16.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 9, 2020
First posted
Jun 12, 2020
StartActual
Jan 11, 2021
Primary completionActual
Jun 30, 2022
CompletionActual
Aug 7, 2024
Results first posted
Oct 30, 2024
Last update
Oct 30, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 30, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT04429555
Lead sponsor
MediciNova
Responsible party
Sponsor
First posted
Jun 12, 2020
Start date
Jan 11, 2021
Primary completion
Jun 30, 2022
Completion
Aug 7, 2024
Results posted
Oct 30, 2024
Last update
Oct 30, 2024

Study contacts

Kazuko Matsuda, MD PhD MPH
study chair · Medicinova Inc

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ibudilast

Start the discussion